GlassScriptPhysician profile
Jason S Davis
NPI 1801321120
$11,195.96
in general payments reported to CMS, 2019-2025
20 companies · $3,131 in 2025
The $3,131 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,918 · 2020: $487 · 2021: $686 · 2022: $1,063 · 2023: $1,132 · 2024: $2,779 · 2025: $3,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,986 · Food and Beverage: $3,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,985.83 |
| Food and Beverage | $3,056.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $5,020.78 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,507.71 | 2019-2021 | |
| Alcon Vision LLC | $1,021.28 | 2019-2025 | Precision7, Total30, Dailies Total1 |
| Bausch & Lomb Americas INC. | $848.03 | 2022-2025 | Infuse, Xiidra, Miebo |
| Johnson & Johnson Vision Care, INC. | $638.17 | 2020-2025 | Acuvue |
| Eyevance Pharmaceuticals LLC | $550.39 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $219.62 | 2019 | |
| Glaukos Corporation | $195.79 | 2019-2025 | Photrexa Viscous and Photrexa |
| Tarsus Pharmaceuticals, INC. | $181.51 | 2024-2025 | Xdemvy |
| Abbvie INC. | $150.02 | 2022 | |
| Astellas Pharma US INC | $138.68 | 2023 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2020 | |
| Optos, INC. | $108.09 | 2019 | |
| Dompe US, INC. | $107.86 | 2023 | Oxervate |
| Sight Sciences, INC. | $82.71 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $76.65 | 2020 | |
| Visionix USA, INC | $74.99 | 2022 | |
| Oyster Point Pharma, INC. | $74.17 | 2022-2025 | Tyrvaya, Ryzumvi |
| Lkc Technologies, INC. | $41.43 | 2025 | |
| Allergan, INC. | $33.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.